SCHEDULE 13G/A: New Enterprise Associates Group Reports Zero Beneficial Ownership in Sagimet Biosciences

New Enterprise Associates 13, L.P. and its affiliated entities and individuals have filed an amended Schedule 13G, declaring no beneficial ownership in Sagimet Biosciences, Inc. as of March 31, 2025.

Summary

• New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, and key individuals including Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad H. Makhzoumi, and Scott D. Sandell, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G.
• As of March 31, 2025, the Reporting Persons beneficially own 0.00 shares of Sagimet Biosciences, Inc.'s Series A Common Stock.
• This translates to 0% of the class of securities represented by the amount beneficially owned.
• The filing indicates that the Reporting Persons hold no sole or shared voting power, nor sole or shared dispositive power over Sagimet Biosciences shares.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as the filing indicates a major institutional investor group (New Enterprise Associates) has no beneficial ownership in Sagimet Biosciences, Inc., which could be interpreted as a lack of confidence or a complete exit from their investment.

Negatives

• The filing indicates that a significant institutional investor group, New Enterprise Associates, no longer holds a reportable beneficial ownership stake in Sagimet Biosciences, Inc. (0% ownership as of March 31, 2025).
• The complete absence of beneficial ownership by a previously significant investor group could be perceived negatively by the market, potentially signaling a lack of institutional confidence or a complete divestment.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Sagimet Biosciences, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of beneficial ownership changes by an institutional investor group in a publicly traded biotechnology company. The complete absence of a reportable stake by a venture capital firm like New Enterprise Associates, which often invests in early-stage biotech, could be a point of interest for market observers, potentially indicating a shift in investment strategy or a complete exit from the company.

Comparison to Industry Standards

• Not applicable for this type of filing as it pertains to specific beneficial ownership disclosure rather than operational or financial performance, thus direct comparisons to industry-standard company results or projects are not relevant.

Stakeholder Impact

• Shareholders: The absence of a significant institutional investor like New Enterprise Associates could lead to negative market perception and potentially impact the company's stock price, as institutional ownership is often seen as a sign of confidence.

Key Dates

Keywords

Sagimet Biosciences, New Enterprise Associates, SEC filing, Schedule 13G/A, beneficial ownership, institutional investor, common stock